Plasmid Manufacturing For Gene Therapy: An Outsourcing Partnership

The rapidly growing field of cell and gene therapy (CGT) is generating overwhelming excitement across the industry. The potential they offer in addressing previously unmet medical needs opens the door to revolutionizing patient care. Significant growth is expected to continue, with an anticipated value of $12 billion by 2025 and the FDA’s expectation of 30 to 60 approved CGT products by 2030.¹